E-viri
Recenzirano
Odprti dostop
-
Amato, Maria Pia; Bergamaschi, Roberto; Centonze, Diego; Mirabella, Massimiliano; Marfia, Girolama Alessandra; Totaro, Rocco; Lus, Giacomo; Brescia Morra, Vincenzo; Aguglia, Umberto; Comi, Cristoforo; Cavalla, Paola; Zaffaroni, Mauro; Rovaris, Marco; Grimaldi, Luigi Maria; Leoni, Stefania; Malucchi, Simona; Baldi, Eleonora; Romano, Marcello; Falcini, Mario; Perini, Paola; Assetta, Maurizio; Portaccio, Emilio; Sommacal, Sergio; Olivieri, Nunzio; Parodi, Franco; Todaro, Daniele Santo; Grassivaro, Nicoletta; Farina, Alberto; Mondino, Margaret Mary; Filippi, Massimo; Trojano, Maria
Journal of neurology, 10/2023, Letnik: 270, Številka: 10Journal Article
Background Cognitive impairment (CI) is a prevalent and debilitating manifestation of multiple sclerosis (MS); however, it is not included in the widely used concept of No Evidence of Disease Activity (NEDA-3). We expanded the NEDA-3 concept to NEDA-3 + by encompassing CI assessed through the Symbol Digit Modality Test (SDMT) and evaluated the effect of teriflunomide on NEDA3 + in patients treated in a real-world setting. The value of NEDA-3 + in predicting disability progression was also assessed. Methods This 96-weeks observational study enrolled patients already on treatment with teriflunomide for ≥ 24 weeks. The predictiveness of NEDA-3 and NEDA-3 + at 48 weeks on the change in motor disability at 96 weeks was compared through a two-sided McNemar test. Results The full analysis set (n = 128; 38% treatment naïve) featured relatively low level of disability (baseline EDSS = 1.97 ± 1.33). NEDA-3 and NEDA-3 + statuses were achieved by 82.8% and 64.8% of patients, respectively at 48 weeks vs. baseline, and by 57.0% and 49.2% of patients, respectively at 96 weeks vs. baseline. All patients except one were free of disability progression at Week 96, and NEDA-3 and NEDA-3 + were equally predictive. Most patients were free of relapse (87.5%), disability progression (94.5%) and new MRI activity (67.2%) comparing 96 weeks with baseline. SDMT scores were stable in patients with baseline score ˃35 and improved significantly in those with baseline score ≤ 35. Treatment persistence was high (81.0% at Week 96). Conclusion Teriflunomide confirmed its real-world efficacy and was found to have a potentially beneficial effect on cognition.
Avtor
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.